Sign inJoin free

Watch / Three stocks for...

Overlooked biotech stocks

23 Sept 20245:59

Overlooked biotech stocks

General information only. ausbiz videos are general information only, produced by Ausbiz TV Pty Ltd, a media business that doesn’t give financial advice. They don’t take into account your objectives, financial situation or needs. Consider whether it’s right for you and read the PDS and TMD before acting on anything you watch.

About this video

Key points:

  • Surge in biotech investments post-Covid, driven by undervalued assets.

  • Importance of spreading risk in the binary outcome nature of biotech.

  • Challenges in the Australian market and the need for US funding.

Reece O'Connell from Merchant Funds Management discusses the current surge in biotech investments. The Merchant Biotech Fund is expanding due to strong investor demand, driven by opportunities in small-cap markets post-Covid. Reece highlights the contrarian approach, focusing on undervalued assets overlooked by the market.

Reece cites successful investments like Polynovo (ASX: PNV) and Dimerix (ASX:DXB), emphasizing the importance of detailed analysis. He acknowledges the binary nature of biotech outcomes but stresses spreading risk across multiple assets to mitigate losses. The importance of interest rate cycles, especially in the US, is also noted as a key factor influencing biotech investments.

Reece explains the challenges in the Australian biotech market, highlighting the need for companies to seek US funding for better valuations. Despite this, he sees it as an opportunity for investors to capitalise on undervalued assets that may eventually be picked up by US firms.

Full unedited transcript:

0:00

Now get into biotech investment, and Merchant Biotech Fund is set to expand on the back of its strong investor demand. To talk us through. It is portfolio manager from Merchant Funds management Reese O'Connell. Reese, welcome to us biz. Thanks for joining us. All right. So why are we seeing this demand at the moment?

0:21

Um, I think the biotech market and the small cap market in particular has come off a pretty low base out of Covid. Uh, there's been, um, sort of investor demand pick up over the last 12 months. We've been calling that, um, now for a couple of years, uh, and that's really driven, um, especially in Australia, um, on such good opportunities, early stage opportunities that have been, uh, rather contrarian or overlooked, um, out of the back of Covid where, you know, biotech was, um, you know, heavily discounted. So like for an example, three months ago up there was 225 million bought in the 40 cent range. It's trading $0.71 now. Um, so you can see the investment is certainly back in the sector. Um, the US uh, is is bouncing obviously and Nasdaq on uh, close to all time highs. And the Russell the small cap indexes is flying along and outperforming. So I think investors are seeing opportunity in the biotech sector now coming from such a long way

1:21

back.

1:22

And Rhys can you give us a view of your strategy there at merchant funds as to, um, how you choose those companies to invest in and perhaps what you are investing in at the moment? Yes, certainly. So we're rather contrarian. So we like to look at assets that have been overlooked by the market. Um, the early stage to late stage. So, um, we've been in a number of stories, uh, Polly Novo being a great one from incubation. But then there's other stories like Dxp, uh, dimeric, which has gone from $0.06 to 60 recently. Phase three. Um drug. Um, so things that the market sort of overlooked, um, and uh, we see value in when we do our own data detailed work. We've got a number of good assets in the portfolio. Now we've got another one. Um, Ayla. Um, so Arabella Therapeutics is a early stage cell therapy, but it's an off the shelf cell therapy. Overlooked by the market? We believe so. A bit of a contrarian investment. So that's what we're really looking for. Investments that, um, at any stage that we feel the market's best or

2:22

mispriced.

2:24

I mean, it is such a difficult segment to operate innocent because, um, these outcomes for biotechs tend to be binary. Uh, given that hit or miss nature, how do you sort of mitigate that risk if you like? It's hard to mitigate it totally because impossible to see what the future outcome will be as you're aware. So we try and spread our risk over, uh, a number of assets. And, you know, if you have a hit rate in biotech or two out of ten, you're going to do really well if you're a long only fund. Um, so we're, you know, we're hitting it a much higher rate than that. Touchwood. Um, so, um, yeah, we we understand that there's going to be investments that don't go our way. But, you know, when we do get them, right. Uh, it's the George Soros approach. It's, um, how much you make when you get it right as against a, you know, how much you lose when you when you're wrong. So you cut your losers if you can and get out and you try and, um, you know, take that long only approach where you can run, incubate an asset, run all the way through or get

3:24

a later stage asset that we feel is undervalued and get to, um, commercialization sooner.

3:32

Where do you see biotech in in terms of its cycle at the moment? I guess take into account what's going on on a macro level. I mean, how important is it the fact that, um, at least globally, interest rates are starting to ease?

3:45

Yeah. And that's a really good point. And you saw that with the Russell, uh, just pricing in, um, the Fed's rate cut recently that was that outperformed all indexes. Um, so I think the small cap market, the small cap market and biotech, that's hugely positive, a lower interest rate market in the US, that's that's coming in Australia. It's yet to be determined whether it's an hour in the next three, six months, early next year. But all indication would be that rate cycle could have peaked. And that's a really good sign for us here. Um, and that's a really good sign if you've incubated or you've got invested in good biotech now into a stronger market, we're probably, you know, starting to get in the midpoint of that cycle or early stage, just with the amount of money that's been raised by companies recently, uh, and, and oversubscribed raises. And we see the broker data and we get pitched a lot of deals. So there's a lot more flow coming in internationally and nationally and locally into biotech. Um, capital raises and

4:44

supporting, um, the story. So, um, yeah, we believe we've come off the lows and now it's a time to to get set into a, into a good period is it's still a difficult environment in Australia in which to operate because I mean here so often that I mean, if there is, uh, actually, you know, biotech comes up to the point of commercialization. They are often forced to, to go overseas. How would you describe that environment at the moment?

5:13

Um, look, the ASX, for example, the Australian market, we feel that it's severely undervalued, comparative to, for example, the US. But typically you need to go to the US. Um, you know, to, to get bigger funding, Nasdaq listings or a big pharma take out of the US and to have been a prime example of that, um, recently. So I think we'll always be the smaller cousin, as it were, to the US, but that as an investor that offers great opportunity because often the assets are overlooked and the value is in the sector, and if the asset is right and gets all the way through, um, the US pick it up. And as you've seen, they've they pay valuations much higher than what, um, you typically get from an Asian um, Australian market.

More like this

We value your privacy

We use essential cookies to make the site work. Non-essential cookies help us improve the experience. You can accept or reject non-essential cookies. Privacy policy